

Gouty Arthritis Global Market 2024 To Reach \$4.57 Billion By 2028 At Rate Of 7.3%

The Business Research Company's Gouty Arthritis Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033

LANDON, GREATER LANDON, UK, July 22, 2024 /EINPresswire.com/ -- The [global gouty arthritis market](#) is set to grow from \$3.21 billion in 2023 to

\$3.44 billion in 2024, at a compound annual growth rate (CAGR) of 7.2%. This growth trajectory is expected to continue, with the market reaching \$4.57 billion by 2028 at a CAGR of 7.3%, driven by factors such as increasing obesity rates, advancements in healthcare infrastructure, and heightened awareness of gout and its treatment.



The Business
Research Company

Gouty Arthritis Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033



It will grow to \$4.57 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%."

*The Business Research
Company*

Rising Prevalence of Obesity Drives Market Growth

The increasing prevalence of obesity is a major factor driving the growth of the gouty arthritis market. Obesity, characterized by an excessive buildup of body fat, is linked to a higher production of uric acid and reduced excretion, which leads to the accumulation of uric acid crystals in

joints. This exacerbates inflammation and pain associated with gout. According to the World Health Organization, around 1 billion individuals were classified as obese in March 2022, and this figure is projected to rise, emphasizing the need for effective gouty arthritis treatments.

Explore comprehensive insights into the global gouty arthritis market with a detailed sample report: https://www.thebusinessresearchcompany.com/sample_request?id=16070&type=smp

Key Players and Market Trends

Major companies in the gouty arthritis market include Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol Myers Squibb, AstraZeneca plc, Novartis International AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc.,

Viatrix Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, UCB S.A., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Horizon Therapeutics plc, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals Inc., and Lupin Pharmaceuticals Inc. These companies are focusing on developing novel therapies, such as Cortrophin Gel, which received FDA approval in October 2023 for the adjunctive treatment of acute gouty arthritis flares.

Major Trends in the Market

The forecast period will witness several significant trends, including a growing demand for effective treatment options, advancements in regenerative therapies, and increased product launches and regulatory approvals. These trends reflect the ongoing efforts to improve treatment outcomes for gouty arthritis and address the rising incidence of the condition.

Segments:

- Type: Acute Gouty Arthritis, Chronic Gouty Arthritis
- Treatment: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Pain Reliever, Corticosteroids, Xanthine Oxidase Inhibitors, Uricosurics, Others Treatments
- Diagnosis: Joint Fluid Test, Blood Test, X-Ray Imaging, Ultrasound, Dual Energy Computed Tomography (CT) Scan, Other Diagnosis
- Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Others Distribution Channels
- End-Users: Hospitals, Specialty Clinics, Other End-Users

Geographical Insights: North America Leading, Europe Fastest-Growing

North America was the largest region in the gouty arthritis market in 2023. However, Europe is expected to be the fastest-growing region during the forecast period, driven by increasing awareness and improved healthcare infrastructure.

Explore the report store to make a direct purchase of the report

<https://www.thebusinessresearchcompany.com/report/gouty-arthritis-global-market-report>

[Gouty Arthritis Global Market Report 2024](#) from TBRC covers the following information:

- Market size data for the forecast period: Historical and Future
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Gouty Arthritis Global Market Report 2024 by [The Business Research Company](#) is the most comprehensive report that provides insights on gouty arthritis market size, gouty arthritis market drivers and trends, gouty arthritis market major players, competitors' revenues, market positioning, and market growth across geographies. The gouty arthritis market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:

Arthritis Monoclonal Antibodies Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/arthritis-monoclonal-antibodie-global-market-report>

Psoriatic Arthritis Treatment Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/psoriatic-arthritis-treatments-global-market-report>

Rheumatoid Arthritis Drugs Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/rheumatoid-arthritis-drugs-global-market-report>

About The Business Research Company

The Business Research Company has published over 15000+ reports covering 27 industries, spanning over 8000+ markets and 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/729432160>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.